QIAGEN (QGEN)
(Delayed Data from NYSE)
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Quest Diagnostics Partners in Pilot Program for COVID-19 Test
by Zacks Equity Research
Quest Diagnostics (DGX) to provide online test results for COVID-19 samples collected via drone-delivered at-home self-collection kits as part of a pilot program.
NuVasive Banks on Product Launches Amid Procedural Volume Loss
by Zacks Equity Research
NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.
Boston Scientific, Farapulse Sign Deal for Treatment of AF
by Zacks Equity Research
Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
Abbott's MitraClip G4 Receives CE Mark for Treatment of MR
by Zacks Equity Research
Abbott's (ABT) MitraClip G4 is expected to improve MR patients' quality of life post its usage eligibility in Europe and other countries recognizing the CE Mark.
LabCorp Boosts Oncology Offerings With Resolution ctDx Launch
by Zacks Equity Research
This development comes on the heels of LabCorp's (LH) commercial partnership with non-invasive liquid biopsy platform developer, Resolution Bioscience.
Blueprint Medicines Up on Positive Top-Line Data From SM Study
by Zacks Equity Research
Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares up.
Quest Diagnostics New Tests Uptake Strong Amid Coronavirus Woe
by Zacks Equity Research
Heavy demand for COVID-19 molecular testing helps partially offset the base volume decline for Quest Diagnostics (DGX).
Medtronic TYRX Driveline Gets FDA's Breakthrough Designation
by Zacks Equity Research
This development helps Medtronic (MDT) to augment its research work in the space of interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its robust product line and consistent high demand for its critical care products.
Legend Biotech (LEGN) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Legend Biotech (LEGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is QIAGEN N.V. (QGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
by Zacks Equity Research
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Medtronic's (MDT) TYRX Envelope Study Results Encouraging
by Zacks Equity Research
Medtronic's (MDT) TYRX Envelope lowers infection risks and is cost-effective.
QIAGEN (QGEN) Completes Buyout of NeuMoDx, Expands Portfolio
by Zacks Equity Research
QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
Bruker's Buyout of Canopy Biosciences Enhances Portfolio
by Zacks Equity Research
Bruker (BRKR) expands its multi-dimensional immune profiling by adding ChipCytometry tools via the acquisition of Canopy Biosciences.
Intuit, Gildan Activewear, Barrick Gold, QIAGEN and AngloGold Ashanti highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuit, Gildan Activewear, Barrick Gold, QIAGEN and AngloGold Ashanti highlighted as Zacks Bull and Bear of the Day
CVS Health Retail Prescription Volume Grows Despite LTC Woes
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy has become even more relevant now.
Cardiovascular Systems Rides on Launches Amid Coronavirus Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Boston Scientific Launches DBS System in Europe Post Approval
by Zacks Equity Research
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
3 Low-Beta Stocks to Combat Coronavirus-Induced Choppy Market
by Nilanjan Banerjee
To combat market volatility, it is important to create a portfolio of low-beta stocks.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific